Antibodies to lymphocyte activation antigens and uses therefor

• US 6,068,984 A
• Filed: 01/30/1998
• Issued: 05/30/2000
• Est. Priority Date: 04/17/1992
• Status: Expired due to Term

• Current Assignee: Dana-Farber Cancer Institute
• Original Assignee: Dana-Farber Cancer Institute
• Inventors: Tedder, Thomas, Zhou, Liang-Ji
• Primary Examiner(s): SAUNDERS, DAVID A
• Application Number:
  US09/016,649
• Time in Patent Office: 851 Days
• Field of Search: 435/7.21, 435/7.24, 435/2, 435/7.92, 435/30, 435/325
• US Class Current: 435/7.24
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/70503 Immunoglobulin superfamily
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily

Abstract

HB15-related lymphocyte activation antigens, and nucleic acid sequences encoding HB15-related antigens are disclosed. Also disclosed are antibodies reactive with HB15.

Claims

1. A method of separatinq HB15 prositive cells from a population of unrelated cells comprising reacting an antibody that specifically recognizes a polypeptide having the sequence of the extracellular domain, the transmembrane domain, or the cytoplasmic domain of the HB15 protein, said HB15 protein having the amino acid sequence given in SEQ ID NO:

2, with a population of cells and isolating cells to which said antibody binds.

2. A method of identifying cells expressing HB15 comprising reacting an antibody that specifically recognizes a polypeptide having the sequence of the extracellular domain, the transmembrane domain, or the cytoplasmic domain of the HB15 protein, said HB15 protein having the amino acid sequence given in SEQ ID NO:

2, with a population of cells and detecting cells to which said antibody binds.

3. A method of quantitating the amount of HB15 in a serum sample from a patient comprising

providing a serum sample to be analyzed;

reacting an antibody that specifically recognizes a polypeptide having the sequence of the extracellular domain, the transmembrane domain, or the cytoplasmic domain of the HB15 protein, said HB15 protein having the amino acid sequence given in SEQ ID NO;

2, with said sample; and

quantitating the amount of said antibody bound to said sample.

4. A method of separating, HB15 positive cells from a population of unrelated cells comprising reacting a monoclonal antibody that specifically recognizes the HB15 protein having the amino acid sequence given in SEQ ID NO:

2 with a population of cells and isolating cells to which said antibody binds.

5. A method of identifying cells expressing HB15 comprising reacting a monoclonal antibody that specifically recognizes the HB15 protein having the amino acid sequence given in SEQ ID NO:

2 with a population of cells and detecting cells to which said antibody binds.

6. A method of quantitating the amount of HB15 in a serum sample from a patient comprising

providing a serum sample to be analyzed;

reacting a monoclonal antibody that specifically recognizes the HB15 protein having the amino acid sequence given in SEQ ID NO;

2 with said sample; and

quantitating the amount of said antibody bound to said sample.